Prognosis
AstraZeneca's Lynparza Slows Spread of Rare Pancreatic Cancer
- Interim analysis didn’t find higher overall survival rates
- Patients with a gene mutation linked to breast cancer benefit
This article is for subscribers only.
AstraZeneca Plc’s Lynparza, a treatment for breast and ovarian cancers triggered by flaws in a gene called BRCA, appears to be effective against uncommon pancreatic cancers tied to the same mutations.
Patients who took two daily doses of the medicine were half as likely to have their cancer resume growing as those who were given a placebo after first getting chemotherapy. The tumors progressed after about 7.4 months in patients who were taking Lynparza, compared with 3.8 months for those given placebo. In some patients, the benefit lasted more than two years.